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Endometriosis has critical implications for women’s quality of life. However, an overview of the current knowledge
of this issue is limited. The objective of this systematic review was to determine the extent of endometriosis and its
treatment upon women’s health-related quality of life (HRQoL). PubMed, Embase, PsycoINFO, CINAHL and the
Cochrane Clinical Trials were searched up to May 2012, and only studies using standardized instruments to evaluate
HRQoL in women with endometriosis were selected. Our electronic searches identified 591 citations, of which 39
studies satisfied the inclusion criteria including nine qualitative studies and 30 treatment-related studies. Findings
showed that endometriosis impaired women’s HRQoL. Pain was strongly related to a poor HRQoL, and medical or
surgical treatment could partially restore this impairment. No conclusive evidence was available on whether
endometriosis imposed an additional impairment in HRQoL per se, apart from the decrease caused by chronic
pelvic pain, or on the superiority of various hormonal suppression agents. The impacts of disease extent, duration
and fertility status upon HRQoL were inconsistent. In summary, HRQoL was impaired in women with endometriosis,
and medical or surgical treatment to alleviate pain could partially restore this impairment.
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Endometriosis affects about 10% of women of child-
bearing age. Pain symptoms (dysmenorrhea, dyspareunia
and dyschezia) may significantly affect their physical,
mental and social wellbeing [1]. It is also a major cause
of infertility, which in turn causes psychological stress,
low self-esteem and depression [2]. Endometriosis is
often associated with diagnosis delay and high recur-
rence rates, leaving women frustrated and catastrophized
[3,4]. Moreover, this decreased quality of life often pre-
dicts women’s quality-adjusted life-years lost and health
care costs [5]. Thus, endometriosis should be analyzed
by a bio-psycho-social approach and requires individua-
lized treatment [1,3].
Health-related quality of life (HRQoL) is a multi-
dimensional, dynamic concept that encompasses phys-
ical, psychological and social aspects associated with a
disease or its treatment [6]. Over the last two decades,
there has been a growing trend to incorporate* Correspondence: lengjenny@vip.sina.com
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reproduction in any medium, provided the orassessment of HRQoL into clinical studies and routine
clinical management, including that for endometriosis
[7]. However, these studies have been limited by small
sample sizes, inadequately validated instruments, and
heterogeneities between cases and controls. Meanwhile,
the impacts of confounders such as age, income, symp-
tom severity, care-seeking behavior and disease extent
upon HRQoL in endometriosis are uncertain [4].
Given this background, an updated critical overview of the
current knowledge of HRQoL in endometriosis and the ef-
fect of treatment is considered timely. In this systematic re-
view, we therefore identified and evaluated studies in which
standardized instruments were used to assess this subject.
Materials and methods
This systematic review was conducted following the
MOOSE consensus statement [8]. No ethical approval
was needed.
Data sources
Comprehensive literature searches were performed in
Medline/PubMed, Embase, CINAHL, PsycINFO and the
Cochrane Clinical Trials database up to May 2012, usingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 14-item criteria assessing the methodological
quality of included studies [9,10]
1 Socio-demographic and medical data are clearly described
2 Inclusion and/or exclusion criteria are formulated
3 The process of data collection is described (e.g. Interview or
self-report, etc.)
4 The type of treatment is described
5 The results are compared between two groups or more
6 Mean or median and range or standard deviation of time since
diagnosis or treatment is given.
7 Participation and response rates for patient groups have to be
described and have to be >75%.
8 Information is presented about patient/disease characteristics of
respondents and non-respondents or if there is no selective
response.
9 A standardized or valid HRQoL questionnaire is used.
10 Results are described not only for HRQoL but also for the physical,
psychological and social domains.
11 Key findings are clearly stated.
12 An attempt is made to find a set of determinants with the highest
prognostic value.
13 Patient signed an informed consent form before study participation.
14 The degree of selection of the patient sample is described.
Jia et al. Journal of Ovarian Research 2012, 5:29 Page 2 of 9
http://www.ovarianresearch.com/content/5/1/29the search terms ‘quality of life’, ‘health-related quality of
life’, ‘health status measurement’, ‘functional status’ and
‘subjective health status’ in combination with ‘endomet-
riosis’. Additional articles were identified by manually
searching references from the retrieved eligible articles.
Only peer-reviewed articles published in the English lan-
guage were included.
Study selection and data extraction
Studies were selected in a two-stage process. First, the
electronic searches were scrutinized and full manuscripts
of all citations that were likely to meet the predefined se-
lection criteria were obtained by two reviewers. Second,
the reviewers inspected all of the manuscripts to deter-
mine whether they met the following criteria: (i) Partici-
pants: women with surgical and/or histological diagnosis
of endometriosis, with a minimal sample size of 30; (ii)
Interventions: standardized instruments/questionnaires
to measure HRQoL; (iii) Outcomes: HRQoL measure-
ments by more than one dimension; and (iv) Study de-
sign: no study design restriction.
For any duplicate publications, the most complete and
relevant versions were included. We extracted data on
general study characteristics, patients’ demographics,
and questionnaires used systematically onto an extrac-
tion sheet.
Methodological quality assessment
All manuscripts meeting the selection criteria were
assessed for their methodological quality, using a 14-
item standardized checklist with small modifications as
listed in Table 1 [9,10]. When a study met the criteria
strictly, one point was assigned; if not, the default was 0.
A study was considered to be of ‘high quality’ if it scored
≥ 10 points. Studies scoring 7–10 points were rated as
‘moderate quality’, while those scoring < 7 points were
deemed of ‘low quality’ [9,10].
Data synthesis
We identified potential effectors on HRQoL in endomet-
riosis by defining five levels of evidence [9,11] as follows:
(i) strong evidence, meaning consistent findings (≥ 75%)
in at least two high quality studies; (ii) moderate evi-
dence, meaning consistent findings (≥ 75%) in one high
quality study and at least one low quality study; (iii)
weak evidence, meaning findings in one high quality
study or consistent findings (≥ 75%) in at least three or
more low quality studies; (iv) inconclusive evidence,
meaning inconsistent findings, or fewer than three low
quality studies available; and (v) no evidence with no
data presented. We did not attempt to pool data across
studies because of the substantial heterogeneities in pa-
tient characteristics and choice of HRQoL instruments.Results
Literature identification, study characteristics and quality
The flow diagram of literature identification and selec-
tion is summarized in Figure 1. A total of 591 citations
were identified by electronic searches. After detailed
evaluation and inspection of the manuscripts, 39 pri-
mary articles met the inclusion criteria. The patient
sample size of the included studies ranged from 33 to
1418, with methodological quality scores ranging from 6
to 13. The salient features of each study are provided in
Additional file 1 and 2.
Of these studies, nine aimed to quantify the impact of
endometriosis upon HRQoL, with [4,12-15] or without
[3,5,16,17] comparison to women without endometriosis.
The remaining 30 studies were treatment-related discuss-
ing the impact of various interventions upon HRQoL in
endometriosis: medical treatment studies [18-31]; surgi-
cal treatment studies [32-44]; and complementary ther-
apy studies [45-47]. The extent of endometriosis,
demographics, symptoms and endometriosis treatments
upon women’s HRQoL are listed in Tables 2, 3, 4.
HRQoL instruments and measures for endometriosis
A total of nine instruments for measurement of HRQoL
in endometriosis were identified. Generic HRQoL ques-
tionnaires - used to capture a broad range of physical,
mental and social health variables - were used in all but
four studies [28,42,43,46]. The SF-36 was used in more
than half of the studies. The Endometriosis Health Profile-
30 (EHP-30) is the only validated disease-specific HRQoL
Figure 1 Study selection process for HRQoL in endometriosis.
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explored this instrument [24,25,28,42,43,46] and its brief
version [17], the Endometriosis Health Profile-5, to assess
HRQoL. A detailed analysis of these instruments is outside
the scope of this review.
HRQoL impairment in women with endometriosis
Endometriosis impaired women’s HRQoL compared
with healthy controls [3-5,13,14,16,17]. In 2008, a case–
control study in Brazil reported that women with endo-
metriosis and chronic pelvic pain (CPP, n = 93) showedTable 2 HRQoL impairment in women with endometriosis
Evidence Reference
EMS vs. healthy Strong ↓ [3-5,13,14,16,17]
EMS-related CPP vs. CPP Inconclusive ↓ [4,12,13]
EMS-related vs. idiopathic infertility Weak ↓ [15]
Abbreviations: EMS, endometriosis; CPP, chronic pelvic pain; ↓, more
impairment.impairment of all domains of the SF-36 (except for role-
related emotional functioning) and higher levels of per-
ceived stress than 82 healthy volunteers [14]. Two other
studies from Brazil [3,16] also found worse HRQoL
scores and higher depression and anxiety rates in endo-
metriosis. It was also reported that endometriosis was
associated with greater losses in work productivity
[3,4,13,17] and increased sexual dysfunction [13]. More-
over, decreased HRQoL was the most important pre-
dictor of health-care cost [5].
However, in comparison to women with similar CPP
symptoms, whether endometriosis had more impairment
upon HRQoL was inconclusive [4,12,13]. According to
the Global Study of Women’s Health, women with endo-
metriosis (n = 745) reported more HRQoL impairment
and work productivity loss than those with similar symp-
toms (n = 587) - especially for the physical component
[4]. However, inconsistent findings were reported in the
other two studies with small sample sizes [12,13].
Women with CPP attributed to endometriosis or not
Table 3 Impact of demographics and symptoms on HRQoL





Marital status X- [3,16]
Fertility status X↓ [3,16,17]
rAFS stage X↓ [3,4,13,15,16]
Pain intensity X↓ [3,4,12-14,16]
Duration X↓ [3,4,16]
Exercise X↑ [16]
Abbreviations: ↑, positively associated with HRQoL; -, no association with HRQoL; ↓, negatively associated with HRQoL.
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[12] and sexual satisfaction [13].
Infertile women secondary to endometriosis reported
higher levels of perceived stress and a lower HRQoL
than did women with idiopathic infertility, according to
the only available high-quality study from Germany, with
no significant difference in social support [15].
Impact of demographics and symptoms on HRQoL
Women of advanced age were reported to suffer more
depressive symptoms than did younger women [3].
However, no such correlation was found by another
study [16]. Employed women were significantly less




Add-back vs. GnRHa X↑















Abbreviations: ↑, positively associated with HRQoL; -, no association with HRQoL; ↓,
OC, oral contraceptive; LUNA, laparoscopic uterosacral nerve ablation; PSN, presacra
medicine.who took regular exercise [16]. Marital status [3,16], in-
come and education level [3,4] were not associated with
HRQoL impairment. However, two of the three studies
enrolled women mainly from low-income socioeconomic
status groups [3,16].
Pain was strongly related to a poor HRQoL. Women
with severe pain were more likely to report higher levels
of HRQoL impairment, depression, anxiety, sexual dys-
function, and more work productivity loss [3,4,12-14],
although Marques et al. denied this correlation [16].
With respect to infertility, no consistent conclusion
could be made [3,16,17]. Infertility significantly impaired
the physical and mental status in endometriosis [17].
















negatively associated with HRQoL; ↑-, similar effective in HRQoL improvement;
l neurectomy; PMR, progressive muscular relaxation; CHM, Chinese herb
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[3], and Marques et al. even reported that women with
children scored lower than women without children in
the functional capacity dimension, according to the
SF-36 [16].
The impacts of rAFS stage [3,4,13,15,16] and disease
duration [3,4,16] upon HRQoL were inconsistent.
Advanced rAFS stages were reported to negatively influ-
ence work productivity and HRQoL [4,15]. In contrast,
Marques et al. reported that women with advanced
stages of endometriosis scored better on mental health
and emotional role limitation domains [16]. However,
most studies revealed no correlation between psychiatric
symptoms and rAFS stages [3,13]. No correlation be-
tween psychiatric symptoms and diagnosis delay was
found in two Brazilian studies [3,16], although a multi-
center study revealed that diagnostic delay worsened the
HRQoL [4].
Impact of treatment upon HRQoL
Medical treatment
Hormonal suppression was strongly associated with
HRQoL improvement in women with endometriosis, re-
gardless of the use of gonadotropin releasing hormone
agonist (GnRHa) alone or with hormonal add-back ther-
apy, oral contraceptives (OCs) or progestins. However, it
should be noted that most data before and after treat-
ment were derived from specific arms of randomized
controlled trials (RCTs) with the exception of one pro-
spective cohort study [31].
Six months of GnRHa treatment improved women’s
HRQoL even at one year after treatment, according to the
SF-36 questionnaire [24-27,29], as well as work-related in-
dexes [18,20]. However, contradictory results were
observed with regard to social support [18,20,24,25], sex-
ual function [18,20,24,25] and the psychological general
well-being index (PGWBI) [18,23]. A clinically relevant
increase in anxiety/depression score was observed during
the 6-month GnRHa treatment [20]. Three months of
GnRHa treatment was also associated with HRQoL im-
provement [47], and the pseudomenopausal symptoms it
induced caused less deterioration of HRQoL than that
caused by surgically induced menopause [31]. Consider-
ing 12 months of treatment, satisfaction with pain control
was reported during and at 6 months post-treatment [22].
Notably, an increase in pain and a decrease in HRQoL
were reported by women during one month of GnRHa
therapy [19].
GnRHa plus add-back therapy improved HRQoL in
women with recurrent [22] or intractable endometriosis-
related pain [28]. Moreover, when compared with GnRHa
alone, add-back hormonal therapy was better at improv-
ing the HRQoL at both 3 and 12 months of treatment
and at 6 months post-treatment [22]. When GnRHa wasprescribed for 18 months, significant and similar HRQoL
improvement and pain control from baseline to 18
months were observed in both immediate and delayed
add-back therapy groups, but the former was associated
with better self-image and emotions after a 12-month dis-
continuation, according to the EHP-30 [28].
Progestins were positively associated with HRQoL in
women with endometriosis [20,21,23-25,27,29,30]. Sub-
cutaneous injections of depomedroxyprogesterone acet-
ate (104 mg/0.65 mL) improved all pre-specified scales
of the EHP-30 and SF-36 from baseline to the end of the
6-month treatment and even at the 18-month follow-up
[24,25]. Similar results were reported for dienogest in
women with symptomatic endometriosis [27,29]. Cypro-
terone acetate therapy also improved the HRQoL, psy-
chiatric profile, and sexual function [21], as well as for
medroxyprogesterone acetate therapy [20]. However, the
high dropout rate (n = 12/25) in the later study limited
the authors from drawing a firm conclusion [20]. Post-
operative levonorgestrel intrauterine system (LNG-IUS)
for 12 months improved both physical and mental health
for women with moderate to severe pain related to
endometriosis [30], although inconsistent finding was
reported, possibly due to low sensitivity of the PGWBI
questionnaire applied [23]. Moreover, six months of
therapy with progestins seemed equivalent to that of
GnRHa in improving HRQoL and reducing pain, accord-
ing to six RCTs [20,23-25,27,29]. This effect persisted for
as long as 12 months after discontinuation [27,29].
Therapy with OCs also improved the HRQoL in
women with endometriosis [21,22,26]. Six months of ther-
apy with OCs produced significant pain control and
improvements of all SF-36 domains during treatment
[21,26], as well as in psycho-emotional status and sexual
function (n = 39) [21] at 12 months after discontinuation
(n = 38) [26]. However, Zupi et al. revealed that 12
months of therapy with OCs failed to improve the
HRQoL in women with recurrent pelvic pain (n = 43),
with the symptoms relapsing after discontinuation [22].
Six months of danazol therapy improved the PGWBI
scores significantly from baseline, with no effect on the
quality of work or sexual function scores [18].
With regard to different hormonal agents for treating
endometriosis, no consistent superiority was observed.
GnRHa without add-back therapy produced better pain
relief and HRQoL improvement than did OCs in women
with pain relapse after conservative surgery [22]. In con-
trast, postoperative hormonal suppression with either
GnRHa or OCs for prophylaxis against pain recurrence
showed similar improvement [26]. When considering
OCs versus GnRHa plus add-back therapy, 12 months of
add-back therapy was reported to produce better pain
control, physical function and vitality in patients with
pain relapse after conservative surgery [22]. Continuous
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gestins therapy in improving HRQoL, psycho-emotional
status and sexual function [21].
Surgical treatment
Conservative surgery improved HRQoL in endometriosis
[26,32-34,36,38,39]. A RCT conducted by Abbott et al.
demonstrated that laparoscopic excision of the endome-
triotic tissues was more effective than placebo treatment
for reducing pain and improving HRQoL and sexual ac-
tivity with a 12-month follow-up, albeit with a 30% pla-
cebo response rate [34]. This improvement even
persisted for up to 5 years (n = 176) [36]. Similar find-
ings were also reported by Roman et al., especially for
adolescent women, with a mean of 37.82 months follow-
up [38]. Three other studies (n = 260) with different
objectives also demonstrated the positive effects of con-
servative surgery with up to 24 months of follow-up, al-
though this was not the primary aims of these studies
[26,32,33]. With respect to deep infiltrating endometri-
osis, laparoscopic management was also associated with
significant HRQoL improvement [39].
Laparoscopic colorectal resection was strongly related
to HRQoL improvement for treating colorectal endo-
metriosis, according to six studies including a total of
446 women [35,37,40,42-44]. Laparoscopic colorectal re-
section improved all domains of the SF-36 [37,40], and
this improvement could persist for up to 55 months
[37]. Similar findings were also reported by Meuleman
and colleagues using a multidisciplinary laparoscopic ap-
proach, giving a high fertility rate (n = 29/61) and
gynecological pain relief [42,43]. Moreover, laparoscopic
approach offered a higher pregnancy rate than open sur-
gery with similar improvements in symptoms and in
HRQoL [35]. However, no correlation between the pres-
ence of positive margins and HRQoL amelioration was
observed [44].
There was weak evidence that adjunct neurectomies,
including laparoscopic uterosacral nerve ablation
(LUNA) and presacral neurectomy (PSN), were more ef-
fective than simple laparoscopy [32,33]. In 2003, an
opened RCT conducted by Vercellini et al. reported that
LUNA did not add more HRQoL and sexual function
improvement in women with endometriosis and pre-
dominantly midline dysmenorrhea, compared with lap-
aroscopic conservative surgery alone [32]. With respect
to PSN, better improvements in all domains of the SF-
36 were reported at the expense of chronic constipation
and/or urinary urgency rate [33].
Complementary treatments
Weak evidence existed for the efficacy of complementary
treatments such as dietary therapy, acupuncture, pro-
gressive muscular relaxation (PMR) and Chinese herbalmedicine (CHM) upon HRQoL in endometriosis. Acu-
puncture was reported to improve all domains of the
SF-36 (except for physical role limitation) in women
with symptomatic endometriosis [45]. For CHM therapy,
the only included RCT failed to reveal any additional
benefit [46]. Dietary supplementation for 6 months after
conservative laparoscopy showed a better HRQoL im-
provement than did surgery alone [26]. Recently, a RCT
reported that PMR training was more effective in im-
proving anxiety, depression and HRQoL in endometri-
osis women under GnRHa therapy [47].
Discussion
To assess endometriosis from the woman’s point of view
and to address its associated emotional, sexual and social
problems are the primary goals of endometriosis man-
agement [13]. In this systematic review, we comprehen-
sively evaluated the impact of endometriosis and its
treatment upon women’s HRQoL.
It is not surprising to find that women with endomet-
riosis reported significant impairments in HRQoL, since
pelvic pain intensity was negatively associated with
HRQoL. This finding was also observed in women with
other benign gynecologic conditions, according to a sys-
tematic review conducted by Jones et al. [50]. CPP, the
main and most wildly studies symptoms of endometri-
osis, often bothers women with endometriosis for years
[4], frustrates both patient and clinician [51], and is
associated with work productivity loss and significant
physical and social debility [5].
However, the current evidence does not allow us to
conclude endometriosis imposed more impairment upon
HRQoL than women with similar CPP symptoms. In-
deed, CPP is not a disease but a description of a clinical
condition. Women with CPP often present some degrees
of pain hypersensitivity [52]. And finding in rat model
suggests that peripheral and central sensitization is a
common sense in endometriosis and other pain syn-
dromes such as painful bladder or irritable bowel syn-
drome [53]. Moreover, women with endometriosis have
a higher rate of other comorbid pain syndromes and
may be prone to depression, anxiety and chronic fatigue
[53]. Thus, to consider endometriosis-related CPP in the
context of chronic pain, and to understand commonal-
ities across different forms of chronic pain might provide
an alternative approach to improve HRQoL of these
patients [12].
According to our analysis, different treatment hormonal
agents showed similar efficacy in pain control and in
HRQoL improvement, but with different side effects and
cost profiles. OCs and progestins, with good safety profile,
low cost and tolerability, appear to be the better choices
[20,24-27,29]. When these agents fail, a 12-month treat-
ment with GnRHa is the only recommendation approved
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be started immediately [28]. Conservative surgery could
enhance women’s fertility and temporally restore HRQoL
[1,54]. Adjuvant therapies like CHM and dietary modifi-
cation that inhibit oxidative stress, angiogenesis and in-
flammation observed with endometriosis need more
study. However, it should be noted that the efficacy is
short-term and recurrence is common in both medical
and surgical modalities [32,36,38]. Thus, a multi-
disciplinary strategy involving a pain clinic and counseling
is recommended [1], but unfortunately no comparatively
study was available on their impact upon HRQoL.
Currently, there is no gold standard to assess HRQoL
in women with endometriosis. We identified a total of
nine instruments to measure HRQoL in endometriosis
with different conceptual frameworks, scales, response
formats and scoring systems. However, their psychomet-
ric properties and internal consistency were not well
established in endometriosis [50]. Generic instruments
such as the SF-36 are useful for comparing between dif-
ferent disorders; however, they correlate poorly with pain
intensity and are compromised by the use of medica-
tions in endometriosis [16,36]. Moreover, issues import-
ant and unique to endometriosis, such as infertility,
might not be addressed by generic questionnaires [48].
The EHP-30, based on open-ended exploratory inter-
views with patients, is currently the only validated ques-
tionnaire for endometriosis [48]. Thus, the EHP-30 is
recommended in HRQoL research on endometriosis,
and a combination with generic instruments is needed
when comparing between different disorders.
Our systematic review has several limitations. First,
the high degree of heterogeneity with respect to study
design, patients’ demographics, disease severity, mea-
sures and data presentation hampers interpretation and
synthesis of the included studies. Further, no gold stan-
dards exist to assess the study quality related to HRQoL
[55]. The 14 quality criteria we used have good reliability
to discover predictors of HRQoL impairment [10].
Moreover, the majority of the studies we reviewed did
not correct for possible confounders and determinants
with the highest prognostic value and no sample calcula-
tions were described, although, to some extent, these
confounder problems offset in the data from RCTs. Be-
sides, unpublished studies were not identified, which
could lead to publication bias.
In summary, endometriosis impairs women’s HRQoL
and this impairment can be at least partly and tempor-
ally counteracted repaired with hormonal therapy and
conservative surgery. However, whether endometriosis
itself imposes additional HRQoL impairment in women
with CPP, or on the superiority of various hormonal sup-
pression agents is not conclusive. Prospective study
designs, appropriate adjustment for confounding factors,diverse patient populations, and the use of validated and
disease-specific instruments such as EHP-30 would
greatly enhance our understanding of HRQoL in
endometriosis.
Additional files
Additional file 1: Studies assessing HRQoL in women with
endometriosis, with or without comparisons.
Additional file 2: Studies assessing interventions on HRQoL in
women with endometriosis.
Abbreviations
HRQoL: Health-related quality of life; SF-36: The Short Form – 36; EHP-30: The
Endometriosis Health Profile – 30; CPP: Chronic pelvic pain;
GnRHa: Gonadotropin releasing hormone agonist; OCs: Oral contraceptives;
PGWBI: The psychological general well-being index; RCT: Randomized
controlled trial; LUNA: Laparoscopic uterosacral nerve ablation; PSN: Presacral
neurectomy; PMR: Progressive muscular relaxation; CHM: Chinese herbal
medicine.
Competing interests
None of the authors have a conflict of interest.
Authors' contributions
S-zJ contributed substantially to conception and design analysis, electronic
searches, data extraction, drafted the article, and revised and approved the
final version to be published. J-hL contributed substantially to conception
and design and approved the final version to be published. J-hS performed
the study selection and data extraction, revised the article, and approved the
final version to be published. P-rS contributed to the data extraction and
approved the final version to be published.J-hL contributed substantially to
conception and design and approved the final version to be published. All
authors read and approved the final manuscript.
Acknowledgement
This work was supported by the key clinical projects from the Ministry of
Health, China.
Received: 24 August 2012 Accepted: 1 October 2012
Published: 18 October 2012
References
1. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R,
Hummelshoj L, Prentice A, Saridogan E: ESHRE guideline for the diagnosis
and treatment of endometriosis. Hum Reprod 2005, 20:2698–2704.
2. Jones G, Jenkinson C, Kennedy S: The impact of endometriosis upon
quality of life: a qualitative analysis. J Psychosom Obstet Gynaecol 2004,
25:123–133.
3. Sepulcri RP, Do AV: Depressive symptoms, anxiety, and quality of life in
women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 2009,
142:53–56.
4. Nnoaham KE, Hummelshoj L, Webster P, D'Hooghe T, De Cicco Nardone F,
De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT: Impact of
endometriosis on quality of life and work productivity: A multicenter
study across ten countries. Fertil Steril 2011, 96:366–373.
5. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I,
Brodszky V, Canis M, Colombo GL, Deleire T, et al: The burden of
endometriosis: costs and quality of life of women with endometriosis
and treated in referral centres. Hum Reprod 2012, 27:1292–1299.
6. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life.
Ann Intern Med 1993, 118:622–629.
7. Chien P, Khan K, Mol BW: How to interpret the findings of the eVALuate
study. BJOG 2005, 112:391–393.
8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D,
Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008–2012.
Jia et al. Journal of Ovarian Research 2012, 5:29 Page 8 of 9
http://www.ovarianresearch.com/content/5/1/299. Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV: Quality of life
among long-term breast cancer survivors: a systematic review. Eur J
Cancer 2005, 41:2613–2619.
10. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T:
A systematic review of health-related quality of life in cutaneous
melanoma. Ann Oncol 2009, 20(Suppl 6):i51–i58.
11. Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G:
Physical risk factors for neck pain. Scand J Work Environ Health 2000,
26:7–19.
12. Souza CA, Oliveira LM, Scheffel C, Genro VK, Rosa V, Chaves MF, Cunha Filho
JS: Quality of life associated to chronic pelvic pain is independent of
endometriosis diagnosis--a cross-sectional survey. Health Qual Life
Outcomes 2011, 9:41.
13. Tripoli TM, Sato H, Sartori MG, De Araujo FF, Girao MJ, Schor E: Evaluation
of quality of life and sexual satisfaction in women suffering from chronic
pelvic pain with or without endometriosis. J Sex Med 2011, 8:497–503.
14. Petrelluzzi KFS, Garcia MC, Petta CA, Grassi-Kassisse DM, Spadari-Bratfisch RC:
Salivary cortisol concentrations, stress and quality of life in women with
endometriosis and chronic pelvic pain. Stress 2008, 11:390–397.
15. Siedentopf F, Tariverdian N, Rucke M, Kentenich H, Arck PC: Immune status,
psychosocial distress and reduced quality of life in infertile patients with
endometriosis. Am J Reprod Immunol 2008, 60:449–461.
16. Marques A, Bahamondes L, Aldrighi JM, Petta CA: Quality of life in Brazilian
women with endometriosis assessed through a medical outcome
questionnaire. Journal of Reproductive Medicine for the Obstetrician and
Gynecologist 2004, 49:115–120.
17. Fourquet J, Baez L, Figueroa M, Iriarte RI, Flores I: Quantification of the
impact of endometriosis symptoms on health-related quality of life and
work productivity. Fertil Steril 2011, 96:107–112.
18. Burry KA: Nafarelin in the management of endometriosis: quality of life
assessment. Am J Obstet Gynecol 1992, 166:735–739.
19. Miller JD: Quantification of endometriosis-associated pain and quality of
life during the stimulatory phase of gonadotropin-releasing hormone
agonist therapy: a double-blind, randomized, placebo-controlled trial.
Am J Obstet Gynecol 2000, 182:1483–1488.
20. Bergqvist A, Theorell T: Changes in quality of life after hormonal
treatment of endometriosis. Acta Obstet Gynecol Scand 2001, 80:628–637.
21. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG:
Cyproterone acetate versus a continuous monophasic oral contraceptive
in the treatment of recurrent pelvic pain after conservative surgery for
symptomatic endometriosis. Fertil Steril 2002, 77:52–61.
22. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C: Add-back
therapy in the treatment of endometriosis-associated pain. Fertil Steril
2004, 82:1303–1308.
23. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa ESJ, Podgaec S,
Bahamondes L: Randomized clinical trial of a levonorgestrel-releasing
intrauterine system and a depot GnRH analogue for the treatment of
chronic pelvic pain in women with endometriosis. Hum Reprod 2005,
20:1993–1998.
24. Crosignani PG, Luciano A, Ray A, Bergqvist A: Subcutaneous depot
medroxyprogesterone acetate versus leuprolide acetate in the treatment
of endometriosis-associated pain. Hum Reprod 2006, 21:248–256.
25. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A: Subcutaneous
injection of depot medroxyprogesterone acetate compared with
leuprolide acetate in the treatment of endometriosis-associated pain.
Fertil Steril 2006, 85:314–325.
26. Sesti F, Pietropolli A, Capozzolo T, Broccoli P, Pierangeli S, Bollea MR:
Hormonal suppression treatment or dietary therapy versus placebo in
the control of painful symptoms after conservative surgery for
endometriosis stage III-IV. A randomized comparative trial. Fertil Steril
2007, 88:1541–1547.
27. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa
N: Dienogest is as effective as intranasal buserelin acetate for the relief
of pain symptoms associated with endometriosis–a randomized, double-
blind, multicenter, controlled trial. Fertil Steril 2009, 91:675–681.
28. Al-Azemi M, Jones G, Sirkeci F, Walters S, Houdmont M, Ledger W:
Immediate and delayed add-back hormonal replacement therapy during
ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG
2009, 116:1646–1656.
29. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C: Dienogest is as
effective as leuprolide acetate in treating the painful symptoms ofendometriosis: a 24-week, randomized, multicentre, open-label trial.
Hum Reprod 2010, 25:633–641.
30. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K,
Indhavivadhana S, Leerasiri P: Postoperative levonorgestrel-releasing
intrauterine system for pelvic endometriosis-related pain: A randomized
controlled trial. Obstet Gynecol 2012, 119:519–526.
31. Bhattacharya SM: Health-related quality of life following surgical
menopause and following gonadotrophin-releasing hormone
analogue-induced pseudomenopause. Gynecol Endocrinol 2009,
25:621–623.
32. Vercellini P, Aimi G, Busacca M, Apolone G, Uglietti A, Crosignani PG:
Laparoscopic uterosacral ligament resection for dysmenorrhea
associated with endometriosis: results of a randomized, controlled trial.
Fertil Steril 2003, 80:310–319.
33. Zullo F, Palomba S, Zupi E, Russo T, Morelli M, Sena T: Long-term
effectiveness of presacral neurectomy for the treatment of severe
dysmenorrhea due to endometriosis. J Am Assoc Gynecol Laparosc 2004,
11:23–28.
34. Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R: Laparoscopic
excision of endometriosis: a randomized, placebo-controlled trial. Fertil
Steril 2004, 82:878–884.
35. Darai E, Dubernard G, Coutant C, Frey C, Rouzier R, Ballester M: Randomized
trial of laparoscopically assisted versus open colorectal resection for
endometriosis: morbidity, symptoms, quality of life, and fertility. Ann
Surg 2010, 251:1018–1023.
36. Abbott JA, Hawe J, Clayton RD, Garry R: The effects and effectiveness of
laparoscopic excision of endometriosis: A prospective study with 2–5
year follow-up. Hum Reprod 2003, 18:1922–1927.
37. Dubernard G, Rouzier R, David-Montefiore E, Bazot M, Darai E: Use of the
SF-36 questionnaire to predict quality-of-life improvement after
laparoscopic colorectal resection for endometriosis. Hum Reprod 2008,
23:846–851.
38. Roman JD: Surgical treatment of endometriosis in private practice:
cohort study with mean follow-up of 3 years. J Minim Invasive Gynecol
2010, 17:42–46.
39. Mabrouk M, Montanari G, Guerrini M, Villa G, Solfrini S, Vicenzi C, Mignemi
G, Zannoni L, Frasca C, Di Donato N, et al: Does laparoscopic management
of deep infiltrating endometriosis improve quality of life? A prospective
study. Health and quality of life outcomes 2011, 9:98.
40. Bassi MA, Podgaec S, Dias JA, D'Amico Filho N, Petta CA, Abrao MS: Quality
of Life after Segmental Resection of the Rectosigmoid by Laparoscopy in
Patients with Deep Infiltrating Endometriosis with Bowel Involvement.
J Minim Invasive Gynecol 2011, 18:730–733.
41. Ford J, English J, Miles WA, Giannopoulos T: Pain, quality of life and
complications following the radical resection of rectovaginal
endometriosis. BJOG 2004, 111:353–356.
42. Meuleman C, D'Hoore A, Van Cleynenbreugel B, Beks N, D'Hooghe T:
Outcome after multidisciplinary CO2 laser laparoscopic excision of deep
infiltrating colorectal endometriosis. Reprod Biomed Online 2009,
18:282–289.
43. Meuleman C, Tomassetti C, Dhoore A, Buyens A, Van Cleynenbreugel B,
Fieuws S, Penninckx F, Vergote I, Dhooghe T: Clinical outcome after CO2
laser laparoscopic radical excision of endometriosis with colorectal wall
invasion combined with laparoscopic segmental bowel resection and
reanastomosis. Hum Reprod 2011, 26:2336–2343.
44. Mabrouk M, Spagnolo E, Raimondo D, Derrico A, Caprara G, Malvi D,
Catena F, Ferrini G, Paradisi R, Seracchioli R: Segmental bowel resection for
colorectal endometriosis: Is there a correlation between histological
pattern and clinical outcomes? Hum Reprod 2012, 27:1314–1319.
45. Rubi-Klein K, Kucera-Sliutz E, Nissel H, Bijak M, Stockenhuber D, Fink M,
Wolkenstein E: Is acupuncture in addition to conventional medicine
effective as pain treatment for endometriosis?: A randomised controlled
cross-over trial. Eur J Obstet Gynecol Reprod Biol 2010, 153:90–93.
46. Flower A, Lewith GT, Little P: A feasibility study exploring the role of
Chinese herbal medicine in the treatment of endometriosis. Journal of
alternative and complementary medicine (New York, N.Y.) 2011,
17:691–699.
47. Zhao L, Wu H, Zhou X, Wang Q, Zhu W, Chen J: Effects of progressive
muscular relaxation training on anxiety, depression and quality of life of
endometriosis patients under gonadotrophin-releasing hormone agonist
therapy. Eur J Obstet Gynecol Reprod Biol 2012.
Jia et al. Journal of Ovarian Research 2012, 5:29 Page 9 of 9
http://www.ovarianresearch.com/content/5/1/2948. Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C: Development of an
endometriosis quality-of-life instrument: the endometriosis health
profile-30. Obstet Gynecol 2001, 98:258–264.
49. Jones G, Jenkinson C, Kennedy S: Evaluating the responsiveness of the
endometriosis health profile questionnaire: the EHP-30. Qual Life Res
2004, 13:705–713.
50. Jones GL, Kennedy SH, Jenkinson C: Health-related quality of life
measurement in women with common benign gynecologic conditions:
a systematic review. Am J Obstet Gynecol 2002, 187:501–11.
51. Martin CE, Johnson E, Wechter ME, Leserman J, Zolnoun DA:
Catastrophizing: a predictor of persistent pain among women with
endometriosis at 1 year. Hum Reprod 2011, 26:3078–84.
52. Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen L: Health related
quality of life and quantitative pain measurement in females with
chronic non-malignant pain. Eur J Pain 2005, 9:267–275.
53. Stratton P, Berkley KJ: Chronic pelvic pain and endometriosis: translational
evidence of the relationship and implications. Hum Reprod Update 2011,
17:327–346.
54. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol
2010, 116:223–236.
55. Vistad I, Fossa SD, Dahl AA: A critical review of patient-rated quality of life
studies of long-term survivors of cervical cancer. Gynecol Oncol 2006,
102:563–572.
doi:10.1186/1757-2215-5-29
Cite this article as: Jia et al.: Health-related quality of life in women with
endometriosis: a systematic review. Journal of Ovarian Research 2012 5:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
